Skip to main content
Premium Trial:

Request an Annual Quote

Richard Brennan, Paul Allenza

GeneGo, a St. Joseph, Mich.-based provider of systems biology databases, software, and services, this week announced that Richard Brennan has been appointed director of toxicology. Brennan will lead the MetaTox Consortium, a joint industry and government effort focused on the development of systems biology tools to predict the human toxicity of new compounds.
Prior to joining GeneGo, Brennan was director of molecular and investigative toxicology at Iconix Biosciences. Before that, Brennan was an associate director of pharmacology and cell biology at Cornerstone Pharmaceuticals and a senior scientist at OSI Pharmaceuticals.

The University of Maryland this week announced the appointment of Paul Allenza as the new director of its Biotechnology Research and Education Program, an initiative dedicated to the research, education, and development of biotechnology products and processes for Maryland companies.

Allenza previously spent 13 years with FMC Corporation, as senior research manager and then senior manager of technology acquisition and licensing at the company's research facility in Princeton, NJ.

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.